Please login to the form below

Not currently logged in
Email:
Password:

AZ said to be eyeing Forest takeover bid

Financial Times says pharma companies are in early negotiations

AstraZeneca (AZ) is considering a takeover bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.

The rumour comes shortly after recently appointed Forest chief executive Brenton Saunders announced a major shake-up of the company's operations, including a cost-cutting programme aimed at trimming $500m off its cost base and a $400m share buyback.

The FT suggests AZ financial advisers recently met the senior management at Forest to discuss a cash offer for the company, which is valued at around $15bn, but that the negotiations are still in very preliminary stages.

At that valuation, any bid for Forest could rival the $15.6bn AZ paid for Medimmune five years ago to boost its biologics pipeline, a deal which some have suggested was priced too high.

One of the draws for AZ is that Forest's product pipeline is pretty closely aligned with its own R&D priorities, with a particular focus on treatments for central nervous system (CNS) disorders as well as cardiovascular and respiratory medicine and infectious diseases.

After several pipeline setbacks, AZ has signed a string of acquisition and licensing deals under CEO Pascal Soriot, who took over the reins of the pharma giant last year with a pledge to streamline and reform the business.

Last month the company agreed to pay $440m to buy antibody-drug conjugate (ADC) specialist Spirogen, while in August it bought cancer company Amplimmune in a deal valued at up to $500m. Earlier this year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as US biotechs AlphaCore Pharma and Omthera Pharmaceuticals.

Analysts suggested that the timing of Forest's restructuring drive - in particular with share buyback - may be a defensive measure to make sure it secures a premium price in any buy-out of the business.

Article by
Phil Taylor

4th December 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics